MARGINAL ZONE LYMPHOMA (MZL)

This study tests a new approach for people with untreated marginal zone lymphoma, a slow-growing blood cancer. Participants first get a short course of standard chemotherapy, then a targeted drug called orelabrutinib to keep the cancer under control. The goal is to see if this co…

This early-stage trial tests a new oral drug called NX-2127 in adults with several types of B-cell blood cancers that have come back or not responded to prior treatment. The drug works by breaking down a protein that helps these cancer cells survive. The main goals are to check s…

This study tests two different drug combinations for people newly diagnosed with marginal zone lymphoma, a slow-growing blood cancer. One group gets a new targeted therapy (orelabrutinib) plus two other drugs, while the other gets standard chemo-immunotherapy. The goal is to see …

This Phase 2 trial tests a personalized approach to treating marginal zone lymphoma, a slow-growing blood cancer. Researchers assign patients to different drug combinations based on their risk score, using targeted therapies like obinutuzumab, orelabrutinib, and lenalidomide. The…

This early-phase study tests a new drug called NX-5948 in adults with advanced B-cell blood cancers (like certain leukemias and lymphomas) that have not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The main goa…

This study tests a drug called orelabrutinib, alone or with another drug (CD20 antibody), in 88 people with untreated marginal zone lymphoma. The goal is to see how well the treatment shrinks or controls the cancer. Participants take the drug daily for 6 cycles, and those with mo…

This early-phase trial tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …

This study tests a combination of three drugs (orelabrutinib, rituximab, and lenalidomide) in people with untreated marginal zone lymphoma, a type of blood cancer. The goal is to see if this approach can make tumors disappear completely. About 50 adults with advanced disease will…

This study is a large registry that will follow nearly 3,000 people with blood cancers like chronic lymphocytic leukemia and several types of lymphoma. Researchers will collect information on treatments, how the disease progresses, and patients' quality of life over time. The goa…